Skip to main content

Table 1 Clinical and demographic characteristics, neuroimaging, and patient-reported outcomes

From: The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis

Variable

Median (IQR) or N (%)

N

483

Age (years)

44.5 (36, 51.9)

Disease Duration (years)

8.8 (5.3, 16)

Neutrophil-lymphocyte ratio

2.1 (1.54, 2.9)

Monocyte-lymphocyte ratio

0.2 (0.15, 0.28)

Expanded Disability Status Scale

2 (1, 3)

Gender

 • Female

347 (71.8%)

 • Male

136 (28.2%)

Smoking Historya

 • No

233 (54.2%)

 • Yes

197 (45.8%)

Body mass index (BMI)a

26.2 (22.8, 31.1)

Multiple sclerosis disease category

 • Clinically isolated syndrome

15 (3.1%)

 • Relapsing-remitting

370 (76.6%)

 • Secondary progressive

65 (13.5%)

 • Primary progressive

33 (6.8%)

Disease modifying therapy

 • Untreated

110 (22.8%)

 • Interferon-β

216 (44.7%)

 • Cyclophosphamide

14 (2.9%)

 • Fingolimod

8 (1.7%)

 • Glatiramer Acetate

51 (10.6%)

 • Mycophenolate Mofetil

33 (6.8%)

 • Natalizumab

37 (7.7%)

 • Other

14 (2.9%)

Neuroimaging and patient-reported outcome measures

Median (IQR); N

 Brain parenchymal fraction

0.85 (0.81, 0.88); 334

 Cerebral T2-hyperintense lesion volume (mL)

1.57 (1.27, 2.03); 334

 Center for Epidemiological Studies Depression Scale

29 (24, 36); 479

 Modified Fatigue Inventory Scale

29 (14, 41); 425

 Modified Social Support Scale

85.4 (71.1, 98.4); 477

 SF-36 Physical composite

46.6 (37.9, 54.3); 471

 SF-36 Mental composite

50.9 (42.5, 56.4); 471

  1. Legend: “Other” DMT includes combinations of or more of the following: methotrexate, azathioprine, pulsed glucocorticoids, anti-IL2 agents, rituximab, natalizumab, interferons, glatiramer acetate, cyclophosphamide. Cyclophosphamide, methotrexate and mycophenolate mofetil were occasionally combined with an interferon or glatiramer acetate; otherwise medications are listed as monotherapy. Median and interquartile ranges use data from patient’s most recent available clinical visit. aSmoking history (N = 430), BMI (N = 402)